UBS Upgrades Biogen Stock to 'Buy' Rating

UBS has upgraded its rating for pharmaceutical company Biogen to 'Buy,' setting a new price target of $225. The investment bank suggests that the next 12 months could see a series of pipeline catalysts for the stock, making it an attractive investment relative to its peers.